Bausch Health Companies Inc. Available-for-sale Securities, Amortized Cost Basis
Bausch Health Companies Inc. (BHC) had Available-for-sale Securities, Amortized Cost Basis of $0 as of 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2014-02-28
- 2013-12-31: Available-for-sale Securities, Amortized Cost Basis $0.00.
- 2013-09-30: Available-for-sale Securities, Amortized Cost Basis $0.00.
- 2013-06-30: Available-for-sale Securities, Amortized Cost Basis $0.00.
- 2013-03-31: Available-for-sale Securities, Amortized Cost Basis $4.41M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-28 |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-01 |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-07 |
| 2013-03-31 | $4.41M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $11.20M 10-K · filed 2014-02-28 |
| 2012-03-31 | $1.06M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $4.71M 10-K · filed 2013-02-28 |
| 2011-09-30 | $2.96M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $12.26M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $8.06M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |